Clinical Trial Update: Administration of Autologous Dendritic Cells (DCs) Infected With an Adenovirus Expressing Her-2 [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating autologous dendritic cells infected with an adenovirus expressing Her-2 as a vaccine for breast cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Autologous dendritic cell vaccine expressing Her-2 (dendritic cell vaccine expressing Her-2)

Snippet

Sponsor: Hamilton Health Sciences Corporation | Conditions: Breast Neoplasms | Phase 1 | Status: COMPLETED